4 free views remaining today

hypomyelinating leukodystrophy 10

ICD-10 Codes

Related ICD-10:

Description

Hypomyelinating leukodystrophy-10 (HLD10) is a rare genetic disorder characterized by postnatal progressive microcephaly, which means that the head circumference and brain volume decrease over time [7]. This condition affects the central nervous system and is caused by mutations in specific genes.

Some of the key features of HLD10 include:

  • Postnatal progressive microcephaly
  • Developmental delay or regression
  • Seizures
  • Spasticity or increased muscle tone
  • Ataxia (difficulty with coordination and balance)
  • Nystagmus (involuntary eye movements)

It's worth noting that HLD10 is a rare condition, and more research is needed to fully understand its characteristics and progression [7].

References: [7] - Characterized by postnatal progressive microcephaly, ...

Additional Characteristics

  • Seizures
  • Nystagmus (involuntary eye movements)
  • Developmental delay or regression
  • Postnatal progressive microcephaly
  • Spasticity or increased muscle tone
  • Ataxia (difficulty with coordination and balance)

Signs and Symptoms

Common Signs and Symptoms of Hypomyelinating Leukodystrophy

Hypomyelinating leukodystrophies are a group of rare genetic disorders that affect the development of myelin, the fatty substance that surrounds and protects nerve fibers. The signs and symptoms of these conditions can vary depending on the specific type, but here are some common ones:

  • Babinski sign: A reflex test that indicates damage to the nervous system [10]
  • Cerebellar ataxia: Difficulty with coordination, balance, and movement due to cerebellum dysfunction [10]
  • Cerebral atrophy: Shrinkage of brain tissue, which can lead to cognitive decline and other neurological symptoms [10]
  • Cerebral hypomyelination: Underdevelopment or loss of myelin in the brain, leading to impaired nerve function [10]
  • Choreoathetosis: Involuntary movements, such as twitching or writhing motions [10]
  • Cognitive impairment: Difficulty with thinking, learning, and memory due to brain damage [10]
  • Decreased motor nerve conduction velocity: Slowed transmission of electrical signals along motor nerves, leading to muscle weakness or paralysis [10]

These symptoms can vary in severity and may progress over time. It's essential for individuals affected by hypomyelinating leukodystrophies to receive proper medical attention and care.

References: [1] - Not applicable (this answer is based on the context provided) [2-9] - Not applicable [10] - Context result 10: Clinical features · Babinski sign · Cerebellar ataxia · Cerebral atrophy · Cerebral hypomyelination · Choreoathetosis · Cognitive impairment · Decreased motor nerve conduction velocity

Additional Symptoms

  • Cognitive impairment
  • Babinski sign
  • Cerebral atrophy
  • Cerebral hypomyelination
  • Choreoathetosis
  • Decreased motor nerve conduction velocity
  • ataxia

Diagnostic Tests

To diagnose hypomyelinating leukodystrophy, several diagnostic tests are employed. Here are some of the key tests used:

  • MRI (Magnetic Resonance Imaging): MRI is a crucial test for confirming the diagnosis of hypomyelinating leukodystrophy. It helps to identify characteristic changes in the brain and spinal cord, such as hypomyelination [1].
  • Genetic testing: Genetic testing is essential for diagnosing hypomyelinating leukodystrophies. It involves analyzing DNA samples from affected individuals to identify specific genetic mutations that cause the condition [2].
  • Blood tests: Blood tests can help to rule out other conditions and provide information on thyroid, growth, and puberty hormone levels, which can be helpful in diagnosis [3].
  • Urine tests: Urine tests may also be performed to rule out other conditions.
  • Neuropsychological screenings: These screenings assess cognitive function and behavior, which can be affected in individuals with hypomyelinating leukodystrophy.

It's worth noting that despite these diagnostic tests, hypomyelinating leukodystrophy is still a challenging condition to diagnose, and a combination of clinical presentation, imaging findings, and genetic testing may be required to confirm the diagnosis [4].

References: [1] Context 1 [2] Context 2 [3] Context 6 [4] Context 5

Additional Diagnostic Tests

  • Blood tests
  • Urine tests
  • Genetic testing
  • MRI
  • Neuropsychological screenings

Treatment

Current Drug Treatments for Hypomyelinating Leukodystrophy

While there are no causative treatments available for hypomyelinating diseases, researchers have been exploring various therapeutic options to manage the condition. According to recent studies [9], current treatment is aimed at preventing nerve damage, slowing progression of the disorder, preventing complications, and providing supportive care.

Some medications that may be used to manage symptoms associated with hypomyelinating leukodystrophy include:

  • Oral medications such as baclofen, tizanidine, or clonazepam to manage spasticity [10]
  • Medications to prevent seizures and other neurological symptoms

It's essential to note that these treatments are not curative and may only help alleviate some of the symptoms associated with hypomyelinating leukodystrophy.

References: [9] Mar 22, 2022 - Symptoms of metachromatic leukodystrophy may include seizures ... Gene therapy experimental treatment has been shown to be safe and efficacious. [10] by G Ceravolo · 2024 · Cited by 3 — Managing spasticity, a prevalent problem in leukodystrophies, can be accomplished through oral medications, such as baclofen, tizanidine, or ...

💊 Drug information is sourced from ChEBI (Chemical Entities of Biological Interest) database. Always consult with a healthcare professional before starting any medication. Click on any medication name for detailed information.

Differential Diagnosis

Differential Diagnosis of Hypomyelinating Leukodystrophy

Hypomyelinating leukodystrophies (HLDs) are a group of rare genetic disorders characterized by the absence or reduction of myelin deposition in the brain. Differential diagnosis is crucial to distinguish HLDs from other conditions that may present with similar symptoms.

Other Hypomyelinating Leukodystrophies

  • Other hypomyelinating leukodystrophies, such as Pelizaeus-Merzbacher disease (PMD), can be a differential diagnosis in males. PMD is caused by mutations in the gene encoding for the myelin proteolipid protein.
  • Delayed myelination or other forms of leukodystrophy may also need to be ruled out.

Antenatal Diagnosis

Genetic testing and prenatal ultrasound can help diagnose HLDs before birth, allowing for informed decision-making regarding pregnancy management.

References:

  • [7] - Other hypomyelinating leukodystrophies, especially when there are no typical dental abnormalities.
  • [8] - It is also important to differentiate HLDs from delayed myelination or other forms of leukodystrophy.

Additional Differential Diagnoses

Additional Information

rdf-schema#domain
https://w3id.org/def/predibionto#has_symptom_1751
owl#annotatedSource
t345372
oboInOwl#hasOBONamespace
disease_ontology
oboInOwl#id
DOID:0060788
core#notation
DOID:0060788
oboInOwl#hasDbXref
MIM:616420
oboInOwl#hasExactSynonym
HLD10
rdf-schema#label
hypomyelinating leukodystrophy 10
IAO_0000115
A hypomyelinating leukodystrophy characterized by autosomal recessive inheritance of progressive postnatal microcephaly, severely delayed psychomotor development and hypomyelination that has_material_basis_in homozygous mutation in the PYCR2 gene on chromosome 1q42.
rdf-schema#subClassOf
t345808
IDO_0000664
http://purl.obolibrary.org/obo/GENO_0000148
relatedICD
http://example.org/icd10/E75.01
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class

Medical Disclaimer: The information provided on this website is for general informational and educational purposes only.

It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with questions about your medical condition.